Yu Shen, PhD.
Department of Biostatistics, Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Oestmann Family Foundation Chair for Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Adjunct Member, University Graduate Programs, Texas A&M University, College Station, TX
Adjunct Professor, Department of Statistics, Rice University, Houston, TX
Adjunct Professor, Graduate School of Biomedical Sciences, The University of Texas, Houston, Houston, TX
Research Interests
- Data integration from real-world data and RCTs;
- Machine learning methods in survival data;
- Health economics research;
- Modeling cancer screening data
Education & Training
Postgraduate Training
| 1994-1995 | Postdoctoral Fellowship, Biostatistics, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington |
Experience & Service
Administrative Appointments/Responsibilities
co-lead Data Science Faculty Recruitment Committee, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present
Chair ad Interim, Biostatistics, University of Texas MD Anderson, 2020 - 2024
Other Professional Positions
LIDA Interest Group Program Chair, American Statistical Association, Alexandria, VA, 2017 - 2019
Member of the 2018 ENAR Program Committee, ENAR/The International Biometric Society, Washington, DC, 2017 - 2018
Member of Nominating Committee, ENAR/The International Biometric Society, Washington, DC, 2017
Site Visit Reviewer, NCI Board of Scientific Counselors for Biostatistics branch of NCI Intermural Program National Cancer Institute (NIH), Bethesda, MD, 2014
Secretary/Treasurer of Biometrics Section, American Statistical Association, Unknown, 2013 - 2014
Member of the Conference Program Committee, ICSA-KISS, Portland, OR, 2013 - 2014
Directors of ICSA board, International Chinese Statistical Association, Statesboro, GA, 2011 - 2013
Member, ENAR Program Committee 2011, Eastern North American Region, Reston, VA, 2009 - 2011
Representative for COPSS, ASA Elizabeth Scott Award Selection Committee, Washington, DC, 2000 - 2001
Extramural Institutional Committee Activities
Member, Faculty Recruitment Panel for Data Science, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Cancer Prevention Research Training Program Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Breast Cancer Moon Shot Internal Advisory Board (IAB), The University of Texas MD Anderson Cancer Center, 2021 - 2023
Member, Morgan Welch IBC Program Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, The Pathology & Laboratory Medicine Division Head Search Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Sponsor, Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program, The University of Texas MD Anderson Cancer Center, 2021
Member, HSR Department Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Member, Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, 2018 - 2020
Member, Internal Advisory Board (IAB) for the SPORE in Breast Cancer, The University of Texas MD Anderson Cancer Center, 2016 - 2021
Member, M.D. Anderson Clinical Research Committee (CRC) 1, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, The Biostat Mentoring Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Executive Committee of Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, 2012 - 2018
Member, M.D. Anderson Clinical Research Committee (CRC) 2, The University of Texas MD Anderson Cancer Center, 2009 - 2011
Alternate Member, M. D. Anderson Cancer Center DSBM Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2012
Member, Oversight Committee for Clinical Trial at MDACC, The University of Texas MD Anderson Cancer Center, 2007 - 2012
Member, Data Safety Monitoring Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2011
Member, Rice Joint Program Graduate Student Admission Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2009
Member, Faculty search committee for Epidemiology department, The University of Texas MD Anderson Cancer Center, 2007 - 2008
Chair, GSBS Biomathematics/Biostatistics Graduate Student Admission Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2009
Member, GSBS Biomathematics/Biostatistics Graduate Student Admission Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2009
Member, Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, 2003 - 2007
Member, Faculty Search Committee, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 2001 - 2019
Editorial Activities
Associate Editor, New England Journal of Statistics and Data Science, 2021 - Present
Associate Editor, Contemporary Clinical Trials Communications, Evise, 2015 - Present
Associate Editor, Lifetime Data Analysis, Springer, 2013 - Present
Associate Editor, Biometrics, 2006 - Present
Honors & Awards
| 2024 - Present | Institute of Mathematical Statistics |
| 2014 - 2025 | Conversation with a Living Legend Professorship, MD Anderson Cancer Center |
| 2007 | American Statistical Association, American Statistical Association |
| 2001 | Finalist, Julie and Ben Roger Award for Excellence |
| 1999 - 2001 | Cancer Research and Prevention Foundation award |
| 1994 - 1995 | NIH Post-Doctoral Training Fellowship, Prostate Cancer Screening Research Grants, University of Washington and Fred Hutchinson Cancer Research Center |
| 1988 - 1990 | Smith Fellowship in Mathematics, University of Notre Dame |
| 1988 - 1989 | Richard Sandy Prize in Mathematics, University of Notre Dame |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2022. Data Science: Learning from Clinical Trials, Real-World, and Simulated Data. Conference. The University of Texas M.D. Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS). Houston, TX, US.
- 2021. Data Science: Learning from Clinical Trial, Real-World, and Simulated Data. Conference. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2016. Network meta-analysis for adjuvant chemotherapy regimen for breast cancer. Conference. Informal Biostatistics Lunch Discussion. Houston, TX, US.
- 2012. Role and Promise of Observational Studies in Cancer Research. Conference. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2008. How evidence based research improves patient care: A leukemia study. Conference. Japan Medical Exchange Program, US.
- 2004. Adaptive sample size estimation in clinical trial designs. Conference. University of Texas M.D. Anderson Cancer Center,. Houston, TX, US.
- 2002. Estimation and its exact confidence interval following a hypothesis testing in the Self-designing trial. Invited. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 2000. Early detection for breast cancer: How much can clinical breast cancer examinations add to mammograms?. Invited. Cancer Genetics Network Biostatistics Workshop. Houston, TX, US.
- 2000. Weighted two-sample test statistics for survival data in early detection trials. Invited. University of Texas M.D. Anderson Cancer Center. Houston, US.
- 1998. Statistical Methods for Estimating Quantities in Screening Programs. Invited. University of Texas M.D. Anderson Cancer Center. Houston, US.
- 1998. Sequential Design and Sample Size Selection in Clinical Trials. Invited. University of Texas M.D. Anderson Cancer Center. Houston, US.
- 1996. Parametric Likelihoods for times to multiple competing risk non-fatal events and death. Invited. University of Texas M.D. Anderson Cancer Center. Houston, US.
- 1995. Estimating Asymptotic Durations in Cancer: the AIDS Connection. Invited. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
- 1995. Estimation of Survival Distribution in Heterogeneous Samples and Assessment of Treatment Effects. Invited. University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2024. Learning from multiple sources of data for personalized medicine. Invited. Annual Conference of Texas Statisticians 2024. Houston, Texas, US.
National Presentations
- 2026. Integrating Machine Learning into Survival Analysis through Distribution-free Conformal Prediction. Invited. Department of Biostatistics. Seattle, Washington, US.
- 2025. From Natural History to Mortality: Evaluating Screening Benefit. Invited. Early Detection Research Network (EDRN) Statistics Working Group, US.
- 2025. Unveiling survival insights: How detection methods and screening trial biases shape surrogate and mortality. Invited. Joint Statistical Meeting 2025. Nashville, TN, US.
- 2025. Synergizing multiple data sources to improve risk prediction. Invited. 2025 Lifetime Data Science Conference. New York, NY, US.
- 2025. Machine Learning in Statistical Inference with Survival Outcomes. Poster. SDSS 2025. Salt Lake City, UT, US.
- 2025. Evaluating Cancer Screening Programs: Statistical Methods and Microsimulation Insights. Invited. Seattle, WA, US.
- 2025. Integrating Multiple Data Sources: Enhancing Precision Medicine Risk Prediction. Invited. Madison, WI, US.
- 2024. Combining external aggregate information with primary data to improve statistical efficiency. Invited. JSM 2024. Portland, OR, US.
- 2024. Data Integration in Statistical Inference and Risk Prediction. Invited. Boston, MA, US.
- 2023. Modeling the COVID incubation period. Invited. Making an Impact in the Era of Data Science. Raleigh, NC, US.
- 2022. Leaning from Big Data: Simulated data and real-world data. Invited. Second Penn Conference on Big Data in Population Health Sciences. Philadelphia, PA, US.
- 2022. Evaluation of the nature history of dementia by combining incident and prevalent cohorts from the Nun study. Invited. JSM 2022. Washington DC, US.
- 2022. Data Science: Learning from Clinical Trial, Real-World, and Simulated Data. Invited. Data Science: Learning from Clinical Trial, Real-World, and Simulated Data, US.
- 2019. Density ratio model for analyzing length-biased data. Invited. 2019 Conference of Lifetime Data Science: Foundations and Frontiers (LiDS). Pittsburgh, PA, US.
- 2019. Challenge and promise of observational epidemiological studies in cancer medicine. Invited. Spring Central and Western Joint Sectional Meeting. Honolulu, HI, US.
- 2018. Analysis of Restricted Mean Survival Time for Length-Biased Data. Invited. SAM 2018 4th International Workshop on the Statistical Analysis of Multi-outcome Data. St. Louis, MO, US.
- 2018. Do Advances In Breast Cancer Treatment Render Screening Mammography Not Cost-Effective For Average-Risk Women. Invited. CHPAMS workshop. New Heaven, CT, US.
- 2018. Lead Round Table Discussion: Identifying the Non-identifiable: Non-progressive Cancers in Screened Populations. Invited. Eastern North American Region Spring Meeting 2018 (ENAR). Atlanta, GA, US.
- 2017. Estimation of cancer natural history from cancer screening trials. Conference. Western North American Region of The International Biometric Society. Santa Fe, NM, US.
- 2017. Do Advances in Breast Cancer Treatment Render Screening Mammography Not Cost-effective for Average-risk Women?”. Conference. ISPOR The Professional Society for Health Economics and Outcomes Research. Boston, MA, US.
- 2014. Challenges to Analyzing Survival Data Subject to Biased Sampling. Invited. Biometrics Section. Boston, MA, US.
- 2014. Efficient design for prospective observational studies. Invited. ICSA. Portland, OR, US.
- 2012. Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies. Invited. ICSA. Boston, MA, US.
- 2008. Semiparametric transformation models for length-biased data. Invited. Winemiller Conference: Survival Analysis and its application. Columbia, MO, US.
- 2007. Innovative Designs and Analysis in Clinical Trials - Fully Harnessing Patient Information accrued during a Trial. Invited. Joint Statistical Meeting. Salt Lake City, UT, US.
- 2006. Adaptive Designs in Clinical Trials. Invited. Joint Statistical Meeting. Seattle, WA, US.
- 2006. Adaptive Design and Analysis of Clinical Trials. Invited. ICSA Applied Statistics Symposium. Storrs, CT, US.
- 2005. Session - Innovative Designs in Clinical Trials. Invited. JSM 2005. Minneapolis, MN, US.
- 2005. Session - Adaptive Clinical Trial Designs. Invited. WNAR meeting. Fairbanks, AK, US.
- 2005. Session - Statistical Methods in Cancer Screening. Invited. ICSA Applied Statistics Symposium. Washington DC, US.
- 2005. Adaptive Clinical Trial design. Invited. IBC Adaptive Designs for Clinical Development workshop. Boston, MA, US.
- 2004. Adaptive design for clinical trials with censored survival data. Invited. ICSA Applied Statistics Symposium. San Diego, CA, US.
- 2003. Session - Competing Risks. Invited. WNAR Meeting. Golden, CO, US.
- 2003. Estimation of a parameter and its exact confidence interval following an adaptive design. Invited. International Biometric Society, Eastern North American Region. Tampa, FL, US.
- 2002. Sample size re-estimation for clinical trials with censored survival data. Invited. Joint Statistical Meeting. New York City, NY, US.
- 2002. Estimation of parameter and its exact confidence interval following a hypothesis testing in the self-designing trial. Invited. The Southern Regional Council on Statistics and the American Statistical Association Summer Research Conference in Statistics. Natchez, MS, US.
- 2002. Cancer Screening in New Millennium. Invited. Cancer Screening in New Millennium. Arlington, VA, US.
- 2001. Statistical inference for self-designing clinical trials. Invited. Joint Statistical Meeting. Atlanta, GA, US.
- 2001. Early detection for breast cancer: how much can clinical breast cancer examinations add to mammograms?. Invited. ENAR Spring Meeting. Charlotte, NC, US.
- 2000. Estimation of screening sensitivity and sojourn time distribution. Invited. International Biometric Society (ENAR) Spring Meeting. Chicago, IL, US.
- 1999. Sample-size re-estimate in clinical trials with a one-sided hypothesis. Invited. Joint Statistical Meeting. Baltimore, MD, US.
- 1998. Statistical methods for estimating quantities in screening programs. Invited. Conference for Carcinogenesis Modeling and Risk Assessment, Huntsman Cancer Institute. Park City, UT, US.
- 1998. Statistical inference for self-designing clinical trials with a one-sided hypothesis. Conference. International Biometric Society (ENAR) Spring Meeting. Pittsburgh, PA, US.
- 1997. Parametric likelihoods for times to multiple competing risk non-fatal events and death. Conference. International Biometric Society (ENAR) Spring Meeting. Memphis, TN, US.
- 1995. Weighted Mean Survival Test Statistics: A Class of Distance Tests for Censored Survival Data. Conference. Joint Statistical Meetings. Orlando, FL, US.
International Presentations
- 2026. Conformal Inference in Survival Data. Invited. the 33rd International Biometric Conference (IBC) at Seoul. Seoul, KR.
- 2025. Integrating Machine Learning into Survival Analysis: Conformal Prediction. Invited. 2025 IMS International Conference on Statistics and Data Science (ICSDS), Seville, Spain. Calverton, US.
- 2025. Semiparametric Estimation of Longitudinal Medical Cost Trajectory. Invited. Joint Conference of the Italian and Eastern Mediterranean Regions of the International Biometric Society 2025. Salerno, IT.
- 2025. Transfer learning and uncertainty quantification in survival analysis. Invited. WNAR 2025. Whistler, CA.
- 2024. Integrating Multiple Sources of Data to Improve Statistical Inference. Invited. IMS China International Conference on Statistics and Probability. Yinchuan, CN.
- 2024. Accommodating Time-Varying Heterogeneity in Risk Estimation under the Cox Model: A Transfer Learning Approach. Invited. International Symposium on Nonparametric Statistics (ISNPS). Braga, PT.
- 2024. Synergizing multiple data sources: Enhancing precision medicine risk prediction. Invited. 2024 International Chinese Statistical Association (ICSA) Applied Statistics Symposium. Nashville, US.
- 2024. Data Integration in Statistical Inference. Invited. Barcelona, ES.
- 2024. A Holistic Review of Adaptive Designs and their Regulatory Alignment. Invited. Adaptive Designs and Multiple Testing Procedures Workshop. Ibiza, ES.
- 2023. Adaptive transfer learning approach to improving risk prediction with time-to-event data. Invited. 2023 IMS International Conference on Statistics and Data Science. Lisbon, PT.
Formal Peers
- 2006. Adaptive Clinical Trial Design. Invited. San Antonio, TX, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Cancer Center Support (CORE) Grant |
| Funding Source: | NATIONAL CANCER INSTITUTE |
| Role: | Co-PI |
| ID: | CA016672-50 |
| Date: | 2026 - 2031 |
| Title: | Advancing Transfer Learning Using Surrogates, Family History, and Prior Models |
| Funding Source: | National Institutes of Health |
| Role: | Co-I |
| ID: | R01CA316177 |
| Date: | 2026 - 2027 |
| Title: | Cancer Center Support (CORE) Grant |
| Funding Source: | National Cancer Institute |
| Role: | Key |
| ID: | 5P30CA016672-50 |
| Date: | 2026 - 2028 |
| Title: | Addressing Unmeasured Covariates in Source Cohorts with Transfer Learning for Survival Outcomes |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R21CA312466 |
| Date: | 2026 - 2026 |
| Title: | Transforming Breast Cancer Surgery and Outcomes for Patients with the MasSpec Pen Technology |
| Funding Source: | Baylor College of Medicine |
| Role: | Key |
| Date: | 2024 - 2029 |
| Title: | BC231271: Advancing our Understanding of Metastatic Breast Cancer through Development of a Comprehensive Research Platform |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | HT94252410991 |
| Date: | 2024 - 2028 |
| Title: | Advancing our Understanding of Metastatic Breast Cancer through Development of a Comprehensive Research Platform |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | HT94252410992 |
| Date: | 2023 - 2027 |
| Title: | Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA272806-01A1 |
| Date: | 2022 - 2027 |
| Title: | Statistical Methods for Integration of Multiple Data Sources toward Precision Cancer Medicine |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1R01CA269696-01 |
Selected Publications
Peer-Reviewed Articles
- Lattimore, CM, Wanis, K, Kuerer, HM, Hunt, KK, Giordano, SH, Mitchell, MP, Shaitelman, SF, Tamirisa, N, Shen, Y, Dong, W, Johnson, HM. ASO Visual Abstract 33(11):9594-9595, 2026. e-Pub 2026. PMID: 42401724.
Abstracts
- Ueno NT, Tahara RK, Reuben JM, Gao H, Saigal B, Ujii T, Lucci A, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis, 2018. e-Pub 2018.
- Shen Y. Margins < 2 mm for patients with ductal carcinoma in situ and contraindication for breast conservation with radiotherapy, 2017. e-Pub 2017.
- Shen Y. USE OF RELATIVE RISK RATIOS TO PRESENT UNCERTAINTY IN MICROSIMULATION MODELS WITH MULTIPLE COMPARATORS: AN APPLICATION TO BREAST CANCER SCREENING STRATEGIES, 2017. e-Pub 2017.
- Shen Y, Dong W, Xu Y, Shih YT. DO ADVANCES IN BREAST CANCER TREATMENT RENDER SCREENING MAMMOGRAPHY, 2017. e-Pub 2017.
- Shen Y. Estimation of cancer natural history and overdiagnosis from cancer screening trials, 2017. e-Pub 2017.
- Weiss A, Chi CK, Shen Y, Shaitelman SF, Garvey PB, Bedrosian I, Babiera GV. What factors are associated with reconstruction in the metastatic breast cancer patient? Results from the National Cancer Database, 2017. e-Pub 2017.
- Moreno, A, Lin HY, Bedrosian I, Smith B, Babiera G, Stauder M, Buchholz T, Woodward W, Shen Y, Shaitelman S. Effect of adjuvant radiation therapy with or without regional node irradiation on overall survival in patients with high-risk invasive breast cancer: A National Cancer Database Analysis, 2016. e-Pub 2016.
- Menen RS, Lin HY, Shen Y, Shaitelman S, Bedrosian I, Woodward W, Ueno N, Valero V, Babiera G. Resection of the primary tumor substantially improves median overall survival in patients with Stage IV metastatic inflammatory breast cancer, 2016. e-Pub 2016.
- Menen RS, Lin HY, Shen Y, Shaitelman S, Bedrosian I, Woodward W, Ueno N, Valero V, Babiera G. Resection of the primary tumor substantially improves median overall survival in patients with Stage IV metastatic inflammatory breast cancer. Proceedings of the Society of Surgical Oncology 69th Annual Cancer Symposium, Boston, MA March 2-5, 2016 (Poster Presentation, Abstract #2373536), 2016. e-Pub 2016.
- Barcenas C; Sinha A; Raghavendra A; Syed M; Hsu L; Patangan M; Chavez-Mac Gregor M; Shen Y; Giordano S; Ueno N; Valero V; Tripathy D. Outcomes after chemotherapy in early-stage breast >cancer (EBC) patients who underwent a 21-gene expression assay. e-Pub 2016.
- Fujii T; Kogawa T; Dong W; Litton J; Moulder S; Tripathy D; Hunt K; Iwamoto T; Pusztai L; Lim B; Shen Y; Ueno N. New threshold of ER positivity in early stage HER2- breast cancer. e-Pub 2016.
- Brewster AM, Peterson SK, Bedrosian I, Dong W, Cantor SB, Volk RJ, DuPont H, Shen Y, Parker P. Psychosocial Predictors of Decision Making for Contralateral Prophylactic Mastectomy. e-Pub 2016.
- Tina Shih Y; Dong W; Xu Y; Shen Y. Assessing the Cost-Effectiveness of the American Cancer Society’s Updated Breast Cancer Screening Guideline for Women at Average Risk. e-Pub 2016.
- Lin H, Babiera G, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno NT, Shen Y. Factors Influencing Treatment of Inflammatory Breast Center in The United States, 2015. e-Pub 2015.
- Colfry J, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Patterns of Axillary Surgery in DCIS Patients Within the US National Cancer Database, 2015. e-Pub 2015.
- Colfry J, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Patterns of Axillary Surgery in DCIS Patients Within the US National Cancer Database. Proceedings of the American Society of Breast Surgeons 16th Annual Meeting in Orlando, FL. April 29 - May 3, 2015 (Poster Presentation, Abstract #2145010). JAMA Surgery, 2015. e-Pub 2015.
- Loveland-Jones C, Shaitelman S, Lin H, Shen Y, Bedrosian I, Kuerer HM, Babiera GV. Disparities in the Use of Post-Mastectomy Radiation Therapy for Inflammatory Breast Cancer, 2015. e-Pub 2015.
- Colfry AJ, Lin H, Shen Y, Kuerer HM, Shaitelman S, Babiera GV, Bedrosian I. Factors Associated with DCIS diagnosis: A Population Based Review of the National Cancer Database, 2015. e-Pub 2015.
- Loveland-Jones C, Shaitelman S, Lin H, Shen Y, Bedrosian I, Kuerer HM, Babiera GV. Disparities in the Use of Post-Mastectomy Radiation Therapy for Inflammatory Breast Cancer. Proceedings of the Society of Surgical Oncology 68th Annual Cancer Symposium, Houston, TX March 25-28, 2015 (Poster Presentation, Abstract # 2086390), 2015. e-Pub 2015.
- Colfry AJ, Lin H, Shen Y, Kuerer HM, Shaitelman S, Babiera GV, Bedrosian I. Factors Associated with DCIS diagnosis: A Population Based Review of the National Cancer Database. Proceedings of the Society of Surgical Oncology 68th Annual Cancer Symposium, Houston, TX March 25-28, 2015 (Poster Presentation, Abstract # 2092577). Jama Surgery, 2015. e-Pub 2015.
- Cupp JA, Liu DD, Shen Y, Ueno NT, Alvarez RH, Chavez-Macgregor M, Woodward W, Kogawa T, Babiera G. Factors Influencing Survival in Inflammatory Breast Cancer, 2014. e-Pub 2014.
- Lautner MA, Lin H, Shen Y, Parker C, Kuerer HM, Shaitelman S, Babiera G, Bedrosian I. Disparities in utilization of breast-conserving therapy among breast cancer patients, 2014. e-Pub 2014.
- Parker C, Lin HY, Shen Y, Li L, Lautner MA, Kuerer HM, Shaitelman SF, Babiera G, Cancer Center IBTUOTMA, Houston, Oncology Group TRT, Cancer Center TUOTMA, Houston, TX. Effect of hormone receptor status and local treatment on overall survival for early-stage breast cancer, 2014. e-Pub 2014.
- Lautner MA, Lin H, Shen Y, Parker C, Kuerer HM, Shaitelman S, Babiera G, Bedrosian I. Disparities in utilization of breast-conserving therapy among breast cancer patients. Proceedings of the 2014 ASCO Breast Cancer Symposium, San Francisco CA September 4-6, 2014 (Abstract # 104), 2014. e-Pub 2014.
- Lautner M, Parker C, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. National Trends in Mastectomy Rates from 1998 to 2010, 2014. e-Pub 2014.
- Reuth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of Tri-Modality Treatment Impacts Survival for Patients with Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends from The National Cancer Database, 2014. e-Pub 2014.
- Lautner M, Parker C, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. National Trends in Mastectomy Rates from 1998 to 2010. Proceedings of the Society of Surgical Oncology 67th Annual Cancer Symposium, Phoenix, AZ March 12-15, 2014 (Poster Session, Abstract #1850921), 2014. e-Pub 2014.
- Reuth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of Tri-Modality Treatment Impacts Survival for Patients with Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends from The National Cancer Database. Proceedings of the Society of Surgical Oncology 67th Annual Cancer Symposium, Phoenix, AZ March 12-15, 2014 (Poster Session, Abstract # 1837679), 2014. e-Pub 2014.
- Shaitelman SF, Lin H, Shen Y, Bedrosian I, Bloom ES, Babiera G. Utilization of Accelerated Partial Breast Irradiation (APBI) and Guidline Concordance: Analysis of the National Cancer Database, 2013. e-Pub 2013.
- Shaitelman SF, Lin H, Shen Y, Bedrosian I, Bloom ES, Babiera G. Utilization of Accelerated Partial Breast Irradiation (APBI) and Guidline Concordance: Analysis of the National Cancer Database. Proceedings of the ASCO 2013 Breast Cancer Symposium, San Francisco, CA September 7-9, 2013 (Abstract # 119569), 2013. e-Pub 2013.
- Siefker-Radtke, O;Wen A, Shen S, Stigall Y, McConkey K, Millikan DJ, Randall E. A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC), 2013. e-Pub 2013.
- Hoffman, Niu K, JG ; Shen JG, Y ; Jiang Y, J ; Shah J, JB ; Smith JB, GL ; Davis GL, JW ; Kim JW, J ; Volk J, R ; Kuban R, Giordano D, Smith S, BD. Does the diagnosing urologist influence choice of initial active treatment versus observation in older men with favorable prostate cancer?, 2013. e-Pub 2013.
- Siefker-Radtke, Wen A, Shen S, Stigall Y, McConkey K, DJ;Millikan, RE. A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC), 2013. e-Pub 2013.
- Lai, Shen C, Zhong Y, Whitman Y, Yang G, W ; Wang W, Shaw T, C. Extraction and Insertion of Tumor Masses in Cone Beam Breast CT Images, 2012. e-Pub 2012.
- Shen, Zhong Y, Y ; Lai Y, Wang C, Shaw T, C. Cone Beam Breast CT with a High Resolution Flat Panel Detector-Improvement of Calcification Visibility, 2012. e-Pub 2012.
- Meng, Z (Meng Z, Liu Z, L (Liu L, Shen L, Y (Shen Y, Yang Y, P (Yang P, Cohen P, L (Cohen L, Huo L, Y (Huo Y, Zhao Y, Q (Zhao Q, Ng Q, CS (Ng CS, C S); Chang C, DZ (Chang DZ, D Z); Garrett D, CR (Garrett CR, C R) C. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC), 2011. e-Pub 2011.
- Meng, Z;Liu, L ; Shen L, Yang Y, P (Yang P, Cohen P, L (Cohen L, Huo L, Y (Huo Y, Zhao Y, Q ; Ng Q, CS ; Chang CS, Garrett D, CR. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC), 2011. e-Pub 2011.
- Shen, Yu. Inference of Tamoxifen’s Effects on Prevention of Breast Cancer, 2009. e-Pub 2009.
- Shen, Yu. Semi-parametric Regression Models for Length-biased and Right-censored Failure Time Data, 2008. e-Pub 2008.
- Feng, W, Shen L, Rosen DG, Liu J, Shen Y, Hunt KK, Orlandi R, Bast Jr RC, J-PJ I, Yu Y. CpG island methylator phenotype (CIMP): a novel biomarker to predict new therapy for breast cancer, 2006. e-Pub 2006.
- Shen Y. Adaptive designs in clinical trials, 2006. e-Pub 2006.
- Harris L, Tuziak T, De La Cerda J, Rosen D, Xiao L, Shen Y, Sabichi A, Czerniak B, Grossman HB. Tissue microarray analysis of connexin-26 and Drg-1 in urinary bladder cancer, 2006. e-Pub 2006.
- Shen Y. Bayesian Adaptive Designs for Clinical Trials, 2005. e-Pub 2005.
- Shen Y, Cai J. Sample size re-estimation for clinical trials with censored survival data, 2005. e-Pub 2005.
- Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening, 2005. e-Pub 2005.
- Harris L, De La Cerda J, Czerniak B, Yang Y, Shen Y, Sabichi A, Grossman HB. Tissue microarray analysis of pAKt, PTEN and L-plastin in urinary bladder cancer, 2004. e-Pub 2004.
- Jacobsohn KM, Kamat AM, Shen Y, Troncoso P, Wen S, Babaian RJ. Validation of selection criteria used for predicting extraprostatic cancer extension in patients undergoing nerve sparing radical prostatectomy, 2004. e-Pub 2004.
- Cheng Y, Shen Y. Bayesian Adaptive designs for clinical trials, 2004. e-Pub 2004.
- Madsen LT, Huber NJ, Wen S, Shen Y, Babaian RJ, Wood CG, Wang R. Penile rehabilitation after fadical prostatectomy: A compliance study, 2004. e-Pub 2004.
- Shen, Parmigiani Y, Giovanni. Optimization of Breast Cancer Screening, 2003. e-Pub 2003.
- Shen, Cheng Y, Su-chun. Prediction of cumulative incidence function under additive risk model, 2003. e-Pub 2003.
- Shen Y, Cheng Y. Estimation of a parameter and its exact confidence interval following an adaptive design, 2003. e-Pub 2003.
- Shen Y, Thall P. Parametric likelihoods for times to multiple competing risk non-fatal events and death, 2003. e-Pub 2003.
- Gee J, Montoya R, De LaCerda J, Wen S, Shen Y, Khaled H, Sabichi AL, Grossman HB. COX-2 is Preferentially Expressed in High-Grade Invasive Transitional Cell Carcinoma of the Bladder, 2002. e-Pub 2002.
- Dinney C, Millikan R, Slaton J, Shen Y, Williams D, Logothetis C. Prognostic Significance of Expressiion of Genes Related to Invasion and Metastasis in Locally Advanced Bladder Cancer Treated with Chemotherapy and Surgery, 2002. e-Pub 2002.
- Shen Y. Statistical inference for self-designing clinical trials, 2001. e-Pub 2001.
- Shen Y. Early Detection for Breast Cancer: How Much can Clinical Breast Examinations Add to Mammography?, 2001. e-Pub 2001.
- Thomas M, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H, Davis J, Estey E. Comparison of Fludarabine-containing Salvage Chemotherapy Regimens for Relapsed/Refractory Acute Myelogenous Leukemia (AML), 2001. e-Pub 2001.
- Beran, M, Shen Y, Kantarjian K, Despa S, Estey E. High dose (HD) chemotherapy in high risk (HR) myelodisplastic syndrome (MDS): Covariate adjusted comparison of five regimens, 2000. e-Pub 2000.
- Shen Y, Fisher L. Sample-size re-estimate in clinical trials with a one-sided hypothesis, 1999. e-Pub 1999.
- Shen Y, Fisher L. Statistical inference for self-designing clinical trials with a one-sided hypothesis, 1998. e-Pub 1998.
- Y Shen Y, TR Fleming TR. Weighted mean survival test statistics: a class of distance tests for censored survival data(Ser B 59:269-280,), 1997. e-Pub 1997.
- Shen Y, Thall, PF. Parametric likelihoods for times to multiple competing risk non-fatal events and death, 1997. e-Pub 1997.
- Shen Y, Fleming TR. Weighted mean survival test statistics: a class of distance tests for censored survival data. J R Stat Soc Ser B(Ser B 59:269-280,), 1997. e-Pub 1997.
- Roddey G, Stephens L, Zhang W, Sellin J, Shen Y, Sinicrope F. Expression of p21 (waf1) and p53 genes during human colorectal tumorigenesis: association with apoptosis, 1996. e-Pub 1996.
- Seong D, Thall P, Kantarjian H, Talpaz M, O'Brien S, Swantkowski J, Rios M, Xu J, Shen Y, Zimmerman S, Glassman A, Ramagli L, Robinson J, Keating M, Freireich EJ, Champlin R, Siciliano M. A comparison of the sensitivity of interphases FISH on blood and hypermetaphase FISH on bone marrow for the presence of the Ph chromosome in CML, 1996. e-Pub 1996.
- Sinicrope F, Roddey G, McDonnell T, Shen Y, Stephens L. Progressive increase in apoptotic rates during colorectal tumor progression 110:A595, 1996. e-Pub 1996.
- Sinicrope F, Roddey G, Stephens L, Meyn T, Glober G, Shen Y, Pazdur R. Evaluation of bcl-2 and p53 oncogenes and apoptotic rates as predictors of chemotherapy response in colorectal cancer, 1996. e-Pub 1996.
- Shen Y Fleming T. Mean survival estimator, with applications for two-sample test, 1995. e-Pub 1995.
- HM Kuerer HM, GM Rauch GM, S Krishnamurthy S, EJ Diego EJ, WT Yang WT, Shen Y, Lin H, Lucci A, DL Ramirez DL, TW Moseley TW, JA Mouabbi JA, Boughey JC, SF Shaitelman SF, White RL, KH Hunt KH, MP Mitchell MP, MT Teshome MT, HM Johnson HM, BD Smith BD, Valero AV. Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial.
Book Chapters
- Singh P, Shen Y, Hunt K. Trial Design: Overview of Study Designs. In: Clinical Trials. Springer International Publishing, 37-45, 2020.
- Shen Y, Parmigianni G. Optimization of breast cancer screening strategies. In: Probability, Statistics and Modeling in Public Health. Springer Science and Business Media, Inc, 405-420, 2006.
- Grossman BH, Sabichi AL, Shen Y. Bladder Cancer: Clinical strategies for cancer chemoprevention. In: Cancer Chemoprevention: Strategies for Cancer Chemoprevention, 315-322, 2005.
Patient Reviews
CV information above last modified November 05, 2026